Progress in developing virus-like particle influenza vaccines

Fu Shi Quan, Young Tae Lee, Ki Hye Kim, Min Chul Kim, Sang Moo Kang

Research output: Contribution to journalReview articlepeer-review

42 Citations (Scopus)


Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.

Original languageEnglish
Pages (from-to)1281-1293
Number of pages13
JournalExpert Review of Vaccines
Issue number10
Publication statusPublished - 2 Oct 2016


  • Influenza virus
  • cross protection
  • strain-specific protection
  • vaccines
  • virus-like particles


Dive into the research topics of 'Progress in developing virus-like particle influenza vaccines'. Together they form a unique fingerprint.

Cite this